On Day 1, we attended sessions on biosimilars, gene therapy, “inflationary rebates,” and tech-enabled patient access strategies.

See what we learned from these content tracks.

Day 2 held the keynote address from Scott Gottlieb, former Commissioner of the FDA. Plus, Adam Fein dove into PBM revenue streams, new trends in pharmacy M&A, and how 340B is here to stay.

Read a summary of their presentations here.

The focus of the final day at Asembia was around collaboration. How are new specialty drugs forcing pharmaceutical manufacturers to collaborate directly with employers? How are employers reacting?

Get our notes on Day 3 here.